1
EXHIBIT 10.1
SECURITIES PURCHASE AGREEMENT
SECURITIES PURCHASE AGREEMENT (this "Agreement"), effective as of
December 23, 1998 by and among WavePhore, Inc., an Indiana corporation (the
"Company"), and Castle Creek Technology Partners LLC (the "Purchaser").
The Company wishes to sell to Purchaser, and Purchaser wishes to buy,
on the terms and subject to the conditions set forth in this Agreement, (i) the
number of shares of the Company's common stock ("Common Stock") set forth herein
(the "Funded Shares") and (ii) upon the occurrence of the First Closing (as
herein defined), a Warrant in the form of Exhibit A hereto (the "First Warrant"
and sometimes referred to as a "Warrant" and, when taken together with all of
the warrants issued hereunder, the "Warrants") entitling the holder thereof to
purchase 250,000 shares (such shares, together with shares issued pursuant to
the Second Warrant (as herein defined) (if any), the "Warrant Shares") of Common
Stock; and (iii) upon the occurrence of the Second Closing (as herein defined)
(if any), a Warrant in the form of Exhibit A hereto (the "Second Warrant" and
also sometimes referred to as a "Warrant"). The Funded Shares, the Warrants and
the Warrant Shares are collectively referred to herein as the "Securities".
The Company has agreed to effect the registration of the Funded Shares
and the Warrant Shares under the Securities Act of 1933, as amended (the
"Securities Act"), pursuant to a Registration Rights Agreement of even date
herewith between the Company and the Purchaser (the "Registration Rights
Agreement"). The sale of the Funded Shares and the Warrants by the Company to
the Purchaser will be effected in reliance upon the exemption from securities
registration afforded by the provisions of Regulation D ("Regulation D"), as
promulgated by the Securities and Exchange Commission (the "Commission") under
the Securities Act.
The Company and the Purchasers hereby agree as follows:
1. PURCHASE AND SALE OF SHARES AND WARRANTS.
1.1 Agreement to Purchase and Sell. Upon the terms and subject to the
satisfaction of the conditions set forth herein, the issuance, sale and purchase
of the Funded Shares and Warrants shall be consummated in two (2) separate
closings. The first closing is hereinafter referred to as the "First Closing"
and the second closing is hereinafter referred to as the "Second Closing" (the
First Closing and Second Closing are sometimes referred to herein as a
"Closing").
(a) On the date of the First Closing, subject to the
satisfaction of the conditions set forth in Article 6 hereof, the Company shall
issue and sell to Purchaser, and Purchaser shall purchase from the Company, (i)
879,116 Funded Shares and (ii) the First Warrant. The aggregate purchase price
for the Securities purchased at the First Closing shall be $7,500,000 (such
aggregate consideration being equal to 105% of the closing price of the
Company's Common Stock one day prior to the date of this Agreement, multiplied
by the number of Funded Shares to be purchased at the First Closing). The "Issue
Date" (as defined in the Warrant) for the First Warrant shall be December 24,
1998. The "Exercise Price" (as defined in
2
the Warrant) for the First Warrant shall be equal to $10.66 per share (such
price being equal to 131.25% of the closing price of the Company's common stock
one day prior to the date of this Agreement).
(b) The Company may elect to consummate the Second Closing by
(and only by) delivering a notice satisfying the conditions of this Section (the
"Second Closing Notice") to Purchaser at least one (1) business day prior to the
date that the Company desires to consummate the Second Closing. In the Second
Closing Notice, the Company shall represent to Purchaser that (i) the Company
elects to consummate the transactions contemplated hereby as the Second Closing;
and (ii) the conditions set forth in Section 6.3 hereof have been satisfied with
respect to the Second Closing.
(c) On the date of the Second Closing (if any), subject to the
satisfaction of the conditions set forth in Article 6 hereof, the Company shall
issue and sell to Purchaser and Purchaser shall purchase from the Company (i) a
number of Funded Shares of Common Stock equal to (x) $7,500,000 divided by (y)
105% of the Closing Sale Price (as herein defined) for the Common Stock one day
prior to the Second Closing Notice (if any), and (ii) the Second Warrant. The
aggregate purchase price for the Securities purchased at the Second Closing (if
any) shall be $7,500,000. The "Issue Date" for the Second Warrant shall be the
date on which the Second Closing Notice (as herein defined) is delivered to
Purchaser. The "Exercise Price" for the Second Warrant shall be equal to 131.25%
of the Closing Sale Price of the Common Stock on the Trading Day (as herein
defined) occurring immediately prior to the date on which the Second Closing
Notice is delivered pursuant to Section 1.1(a) hereof. "Trading Day" shall mean
any day on which the Common Stock is traded for any period on the Nasdaq
National Market or on the principal securities exchange or market on which the
Common Stock is then traded. "Closing Sale Price" means, with respect to a
security, the closing sale price per share of such security on the Nasdaq
National Market or on the principal securities exchange or market on which such
security is listed or traded as reported by Bloomberg Financial Markets or, if
Bloomberg Financial Markets is not then reporting closing sale prices of such
security, a comparable reporting service of national reputation selected by the
Company and reasonably acceptable to Purchaser (collectively, "Bloomberg") or if
the foregoing does not apply, the last reported sale price of such security in
the over-the-counter market or the electronic bulletin board for such security
as reported by Bloomberg, or, if no sale price is reported for such security by
Bloomberg, the average of the sale prices of all market makers for such security
as reported in the "pink sheets" by the National Quotation Bureau, Inc. If the
Closing Sale Price cannot be calculated for such security on such date on any of
the foregoing bases, the Closing Sale Price of such security on such date shall
be the fair market value as reasonably determined by an investment banking firm
selected by Purchaser (which may be Purchaser or an affiliate thereof) and
reasonably acceptable to the Company, with the costs of such appraisal to be
borne by the Company.
1.2 Form of Payment. At each Closing, Purchaser shall pay the aggregate
purchase price for the Funded Shares and Warrant being purchased by Purchaser by
wire transfer to the Company, in accordance with the Company's written wiring
instructions, against delivery of duly
3
executed stock certificates for the same, and the Company shall deliver
certificates for such Funded Shares and the Warrant being purchased against
delivery of such aggregate purchase price.
1.3 Closing Dates. Subject to the satisfaction of the conditions set
forth in Article 6 hereof, the date and time of the issuance, sale and purchase
of the Securities pursuant to this Agreement shall be (i) for the First Closing,
on December 24, 1998, and (ii) for the Second Closing, on the day one (1)
business day following receipt by Purchaser of the Second Closing Notice from
the Company. Each Closing shall occur at 12:00 p.m., at the offices of Altheimer
& ▇▇▇▇, ▇▇ ▇. ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇.
1.4 Certain Definitions. When used herein, (A) "business day" shall
mean any day on which the New York Stock Exchange and commercial banks in the
city of New York are open for business, (B) an "affiliate" of a party shall mean
any person or entity controlling, controlled by or under common control with
that party and (C) "control" shall mean, with respect to an entity, the ability
to direct the business, operations or management of such entity, whether through
an equity interest therein or otherwise.
1.5 Limitations on Issuance.
1.5.1 9.9% Limitation. Notwithstanding anything to the
contrary contained herein, the Company shall not sell, and Purchaser shall not
purchase, any Funded Shares at the Second Closing (or thereafter pursuant to
Section 1.5.3 hereof) to the extent (but only to the extent) that, as a result
of such issuance and purchase, Purchaser would beneficially own in excess of
9.9% of the shares of Common Stock then outstanding (including beneficial
ownership of the shares of Common Stock which are beneficially owned on the date
of the First Closing and the 879,116 shares to be purchased at the First
Closing, but disregarding beneficial ownership of any other shares of Common
Stock by Purchaser which are beneficially owned other than by virtue of (i) the
purchase of Funded Shares or (ii) the ownership of other shares at the First
Closing). If as a result of this limitation, the Company does not issue and the
Purchaser does not purchase all of the Funded Shares at Closing, the Warrant to
purchase shares of Common Stock to be issued at the Second Closing shall be
reduced to an amount equal to (x) the number of Funded Shares actually issued
and purchased within this limitation divided by (y) the number of Funded Shares
which would have been issued but for this 9.9% limitation times (z) the original
number of Warrant Shares issuable upon exercise of the Warrant.
1.5.2 NASD Limitation. Notwithstanding anything to the
contrary contained herein, the Company shall not sell to Purchaser, and
Purchaser shall not purchase, at the Second Closing (or thereafter pursuant to
Section 1.5.3 hereof) any Securities in violation of the amount limitations of
NASD Rule 4460, unless the shareholders of the Company shall have previously
authorized such issuance or the issuance shall satisfy the price limitations of
such Rule 4460. For the purposes of this Section 1.5.2, the total number of
shares of Common Stock shall be determined by adding the number of shares of
Common Stock issued to the number of Warrant Shares issuable upon exercise by
the Purchaser of the Warrants. If this limitation results in the
4
Company issuing less than all of the Securities issuable pursuant to the Second
Closing, the Company shall reduce the number of Funded Shares and the number of
shares of Common Stock for which the Warrant is exerciseable proportionately.
1.5.3 Subsequent Issuance. If any Securities are not issued
pursuant to the Second Closing as a result of the limitations of this Section
1.5, during the sixty (60) days immediately following the Second Closing, the
Company may elect to issue by written notice from time to time to Purchaser and,
upon such issuance, Purchaser shall purchase such Securities as may from time to
time be allowable under such limitations, but such issuance and purchase must
exceed an aggregate value of five hundred thousand dollars ($500,000), except
that if the aggregate value of all remaining Securities is less than $500,000,
the issuance and purchase must be of all such remaining Securities. Such
issuance and purchase shall be consistent with all provisions of this Agreement
and all conditions hereto must be met by the applicable party at the time of
each such subsequent issuance. If Securities contemplated by this Agreement
(other than shares underlying the Warrants) remain unissued and unpurchased on
the ninetieth (90th) day after the Second Closing, the Company may remove such
unissued Securities from the Second Registration Statement (as defined in the
Registration Rights Agreement).
For the purposes of this Section 1.5, beneficial ownership and all
determinations and calculations, including without limitation, with respect to
calculations of percentage ownership, shall be made in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13D and
G thereunder.
2. REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS.
Purchaser hereby makes the following representations and warranties to
the Company and agrees with the Company that, as of the date of this Agreement,
as of the signing of this Agreement by the parties and as of the Closing Date:
2.1 Authorization; Enforceability. Purchaser is duly and validly
organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation or organization with full power and authority
to purchase the Funded Shares and the Warrants and to execute and deliver this
Agreement. This Agreement constitutes Purchaser's valid and legally binding
obligation, enforceable in accordance with its terms, except as such enforcement
may be limited by (i) applicable bankruptcy, insolvency, reorganization or other
laws of general application relating to or affecting the enforcement of
creditors' rights generally and (ii) general principles of equity.
2.2 Accredited Investor; Investment Intent. Purchaser is an accredited
investor as that term is defined in Rule 501 of Regulation D, and is acquiring
the Funded Shares and the Warrants solely for its own account for investment
purposes as a principal and not with a present view to the public resale or
distribution of all or any part thereof, except pursuant to sales that are
exempt from the registration requirements of the Securities Act and/or sales
registered under the Securities Act; provided, however that in making such
representation, Purchaser does not agree
5
to hold the Securities for any minimum or specific term and reserves the right
to sell, transfer or otherwise dispose of the Securities at any time in
accordance with the provisions of this Agreement and with Federal and state
securities laws applicable to such sale, transfer or disposition.
2.3 Information. Purchaser has reviewed the Disclosure Documents (as
defined below), including the risk factors disclosed therein, and understands
that an investment in the Funded Shares, the Warrants and the Warrant Shares
involves a high degree of risk. The Company has granted to Purchaser the
opportunity to ask questions of and receive answers from representatives of the
Company, its officers, directors, employees and agents concerning the Company
and materials relating to the terms and conditions of the purchase and sale of
the Funded Shares and the Warrants hereunder. Neither such information nor any
other investigation conducted by Purchaser or any of its representatives shall
modify, amend or otherwise affect Purchaser's right to rely on the Company's
representations and warranties contained in this Agreement.
2.4 Limitations on Disposition. Purchaser acknowledges that, except as
provided in the Registration Rights Agreement, the Securities have not been and
are not being registered under the Securities Act and may not be transferred or
resold without registration under the Securities Act or unless pursuant to an
exemption therefrom. Purchaser agrees not to sell, transfer or otherwise dispose
of the Securities unless and until:
(a) there is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is made
in accordance with such registration statement; or
(b) (i) Purchaser shall have notified the Company in advance
of the proposed disposition, and (ii) if reasonably requested by the Company,
Purchaser shall have furnished the Company with an opinion of counsel (the cost
of which shall be borne by Purchaser), reasonably satisfactory to the Company,
that such disposition will not require registration under the Securities Act. It
is agreed that no advance notice and no opinion of counsel will be required for
the transfer of the Securities to an affiliate of Purchaser or with respect to a
sale thereof made pursuant to Rule 144 under the Securities Act ("Rule 144").
2.5 Legend. Purchaser understands that the certificates representing
the Securities may bear at issuance a restrictive legend (the "Legend") in
substantially the following form:
"The securities represented by this certificate have not been
registered under the Securities Act of 1933, as amended (the
"Securities Act"), and may not be offered, sold, transferred,
pledged, hypothecated or otherwise disposed of unless a
registration statement under the Securities Act and applicable
state securities laws shall have become effective with regard
thereto, or an exemption from registration under the
Securities Act and applicable state securities laws is
available in connection with such offer, sale or disposition.
Such securities are issued subject to the
6
provisions of (i) the Articles of Incorporation of WavePhore,
Inc. (the "Company"), as amended, (ii) a Securities Purchase
Agreement, dated December 23, 1998, by and between the Company
and the purchaser named therein, and (iii) a Registration
Rights Agreement, effective December 23, 1998, by and between
the Company and such purchasers."
Notwithstanding the foregoing, it is agreed that, as long as the resale
of the Funded Shares or the Warrant Shares, as the case may be, is registered
pursuant to an effective registration statement or such shares are eligible for
resale under Rule 144(k), (A) the Warrant Shares shall be issued upon an
exercise of the Warrant pursuant to the terms thereof and (B) the Funded Shares
shall be issued in accordance with the terms of this Agreement, in each such
case without any legend or other restrictive language. The legend set forth
above shall be removed and the Company shall issue a new certificate without
such legend to the holder of any Security upon which it is stamped if (i) the
sale of such Security is registered under the Securities Act, (ii) such holder
provides the Company with an opinion of counsel, in form, substance and scope
customary for opinions of counsel in comparable transactions (the cost of which
shall be borne by such holder) to the effect that such Security can be sold
publicly without registration under the Securities Act, (iii) such holder
provides the Company with reasonable assurances that such Security can be sold
pursuant to Rule 144 without any restriction as to the number of shares of or
represented by such Security that can then be immediately resold or (iv) such
Security has been sold pursuant to Rule 144. In addition, and without limiting
the foregoing, the Company shall use its reasonable best efforts to cause its
transfer agent to electronically transmit the Common Stock issuable to the
Holder by crediting the account of Holder's prime broker with DTC through its
Deposit Withdrawal Agent Commission ("DWAC") system or other electronic delivery
system selected by Holder upon reasonable notice.
3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
The Company hereby makes the following representations and warranties
to Purchaser and agrees with Purchaser that, as of the date of this Agreement,
as of the date of the signing of this Agreement and as of the date of the First
Closing and as of the date of the Second Closing (if any):
3.1 Organization, Good Standing and Qualification. Each of the Company
and its subsidiaries is duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization and has
all requisite corporate power and authority to carry on its business as now
conducted. Each of the Company and its subsidiaries is duly qualified to
transact business and is in good standing in each jurisdiction in which the
failure so to qualify would have a material adverse effect on the consolidated
business or financial condition of the Company and its subsidiaries taken as a
whole. The term "subsidiaries" shall mean entities in which the Company has an
equity interest of 50% or greater.
3.2 Authorization; Consents. The Company has the requisite corporate
power and authority to enter into and perform its obligations under (i) this
Agreement, (ii) the Registration
7
Rights Agreement, (iii) the Warrants and (iv) all other agreements, documents,
certificates or other instruments delivered by the Company at the Closings (the
instruments described in (i), (ii), (iii) and (iv) being collectively referred
to herein as the "Transaction Documents"), to issue and sell the Funded Shares
and the Warrants to such Purchaser in accordance with the terms hereof and to
issue the Warrant Shares upon exercise of the Warrants. All corporate action on
the part of the Company by its officers, directors and shareholders necessary
for the authorization, execution and delivery of, and the performance by the
Company of its obligations under, the Transaction Documents have been taken, and
no further consent or authorization of the Company, its Board of Directors, its
shareholders, any governmental agency or organization, or any other person or
entity is required (other than any consent of such shareholders that may be
required pursuant to Rule 4460 promulgated by the National Association of
Securities Dealers, Inc. (the "NASD") and, with respect to the Registration
Rights Agreement, applicable securities authorities).
3.3 Enforcement. The Transaction Documents constitute valid and legally
binding obligations of the Company, enforceable in accordance with their
respective terms, except as such enforcement may be limited by (i) applicable
bankruptcy, insolvency, reorganization or other laws of general application
relating to or affecting the enforcement of creditors' rights generally and (ii)
general principles of equity.
3.4 Disclosure Documents; Material Agreements; Other Information. The
Company has filed with the Commission: (i) the Company's Annual Report on Form
10-K for the year ended December 31, 1997, (ii) a Quarterly Report on Form 10-Q
for the quarter ended September 30, 1998, (iii) all Current Reports on Form 8-K
required to be filed with the Commission since December 31, 1997 and (iv) the
Company's definitive Proxy Statement for its 1998 Annual Meeting of Shareholders
(all such documents filed after December 31, 1997 are referred to collectively
herein as the "Disclosure Documents"). The Company is not aware of any event
occurring on or prior to the First Closing and will not be aware of any event
occurring prior to the Second Closing (other than the transactions effected
hereby) that would require the filing of, or with respect to which the Company
intends to file, a Form 8-K immediately after the applicable Closing. Each
Disclosure Document, as of the date of the filing thereof with the Commission,
conformed in all material respects to the requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and
regulations thereunder and, as of the date of such filing, such Disclosure
Document did not contain an untrue statement of material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading. Except as described on Schedule 3.4 hereto, all material agreements
required to be filed as exhibits to the Disclosure Documents have been filed as
required; neither the Company nor any of its subsidiaries is in breach of any
agreement where such breach is reasonably likely to have a material adverse
effect on the consolidated business or financial condition of the Company and
its subsidiaries taken as a whole. Any information provided to Purchaser
pursuant to Section 2.3 does not contain an untrue statement of material fact or
omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were
made, not misleading. Except as set forth in the Disclosure Documents or any
8
schedule or exhibit attached hereto, the Company has no liabilities, contingent
or otherwise, other than liabilities incurred in the ordinary course of business
which, under generally accepted accounting principles, are not required to be
reflected in such financial statements and which, individually or in the
aggregate, are not material to the consolidated business or financial condition
of the Company and its subsidiaries taken as a whole. As of their respective
dates, the financial statements of the Company included in the Disclosure
Documents complied as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the
Commission with respect thereto. Such financial statements have been prepared in
accordance with generally accepted accounting principles consistently applied at
the times and during the periods involved (except (i) as may be otherwise
indicated in such financial statements or the notes thereto, or (ii) in the case
of unaudited interim statements, to the extent they may exclude footnotes or may
be condensed or summary statements) and fairly present in all material respects
the financial position of the Company as of the dates thereof and the results of
its operations and cash flows for the periods then ended (subject, in the case
of unaudited statements, to normal year-end adjustments).
3.5 Capitalization. The capitalization of the Company as of the date
hereof, including the authorized capital stock, the number of shares issued and
outstanding, the number of shares issuable and reserved for issuance pursuant to
the Company's stock option plans, the number of shares issuable and reserved for
issuance pursuant to securities (other than the Funded Shares and the Warrants)
exercisable for, or convertible into or exchangeable for any shares of Common
Stock and the number of shares initially to be reserved for issuance upon
exercise of the Warrants in full is set forth on Schedule 3.5 hereto. All of
such outstanding shares of capital stock have been, or upon issuance will be,
validly issued, fully paid and non-assessable. No shares of the capital stock of
the Company are subject to preemptive rights or any other similar rights of the
shareholders of the Company or any liens or encumbrances created by or through
the Company. Except as disclosed on Schedule 3.5, or as contemplated herein, as
of the date of this Agreement and as of the applicable Closing, there are no
outstanding options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights
convertible into or exercisable or exchangeable for, any shares of capital stock
of the Company or any of its subsidiaries, or arrangements by which the Company
or any of its subsidiaries is or may become bound to issue additional shares of
capital stock of the Company or any of its subsidiaries; except, as to the
Second Closing, equity securities permitted pursuant to Section 4.14 and
securities issued in connection with the grant and/or exercise of options by
employees, consultants or directors in the ordinary course of business since the
date of the First Closing.
3.6 Valid Issuance
3.6.1 The Funded Shares are duly authorized and, when issued,
sold and delivered in accordance with the terms hereof, (i) will be duly and
validly issued, fully paid and nonassessable, free and clear of any taxes,
liens, claims, preemptive or similar rights or encumbrances imposed by or
through the Company and (ii) based in part upon the representations of such
Purchaser in this Agreement, will be issued, sold and delivered in compliance
with all applicable Federal and state securities laws.
9
3.6.2 The Warrant Shares are duly authorized and reserved for
issuance and, upon exercise of each Warrant in accordance with the terms
thereof, will be duly and validly issued, fully paid and nonassessable, free and
clear of any taxes, liens, claims, preemptive or similar rights or encumbrances
imposed by or through the Company.
3.7 No Conflict with Other Instruments. Neither the Company nor any of
its subsidiaries is in violation of any provisions of its Certificate of
Incorporation, Bylaws or any other governing document as amended and in effect
on and as of the date hereof or in default (and no event has occurred which,
with notice or lapse of time or both, would constitute a default) under any
provision of any instrument or contract to which it is a party or by which it is
bound, or of any provision of any Federal or state judgment, writ, decree,
order, statute, rule or governmental regulation applicable to the Company, which
would have a material adverse effect on the consolidated business or financial
condition of the Company and its subsidiaries taken as a whole. The (i)
execution, delivery and performance of this Agreement, the Warrants and the
other Transaction Documents, and (ii) consummation of the transactions
contemplated hereby and thereby will not result in any such violation or be in
conflict with or constitute, with or without the passage of time and giving of
notice, either a default under any such provision, instrument or contract or an
event which results in the creation of any lien, charge or encumbrance upon any
assets of the Company or of any of its subsidiaries or, except as disclosed in
Schedule 3.7 hereto, the triggering of any anti-dilution rights on the part of
holders of the Company's securities.
3.8 Financial Condition; Taxes; Litigation.
3.8.1 The Company's financial condition is, in all material
respects, as described in the Disclosure Documents, except for changes in the
ordinary course of business and normal year-end adjustments that are not, in the
aggregate, materially adverse to the consolidated business or financial
condition of the Company and its subsidiaries taken as a whole. Except as
otherwise described in the Disclosure Documents, as of the date hereof and as of
the applicable Closing there has been no, or will not be any, as the case may
be, material adverse change to the Company's business, operations, properties,
financial condition, prospects or results of operations since the date of the
Company's most recent audited financial statements contained in the Disclosure
Documents.
3.8.2 The Company has filed all tax returns required to be
filed by it and paid all taxes which are due, except for taxes which it
reasonably disputes or which could not reasonably be expected to have a material
adverse effect on the consolidated business or financial condition of the
Company and its subsidiaries taken as a whole.
3.8.3 Except as set forth in Schedule 3.8.3, each of the
Company and its subsidiaries is not the subject of any pending or, to the
Company's knowledge, threatened investigation or administrative or legal
proceeding by the Internal Revenue Service, the taxing authorities of any state
or local jurisdiction, the Commission or any state securities commission
10
or other governmental entity which could reasonably be expected to have a
material adverse effect on the consolidated business or financial condition of
the Company and its subsidiaries taken as a whole.
3.8.4 Except as set forth in Schedule 3.8.4, there is no
material claim, litigation or administrative proceeding pending, or, to the
Company's knowledge, threatened, against the Company or any of its subsidiaries,
or against any officer, director or employee of the Company or any such
subsidiary in connection with such person's employment therewith. Neither the
Company nor any of its subsidiaries is a party to or subject to the provisions
of, any order, writ, injunction, judgment or decree of any court or government
agency or instrumentality which could reasonably be expected to have a material
adverse effect on the consolidated business or financial condition of the
Company and its subsidiaries taken as a whole.
3.9 Reporting Company; Form S-3. The Company is subject to the
reporting requirements of the Exchange Act, has a class of securities registered
under Section 12 of the Exchange Act, and has filed all reports required
thereby. The Company is eligible to register for resale by the Purchaser shares
on a registration statement on Form S-3 under the Securities Act.
3.10 Acknowledgment of Dilution. The Company acknowledges that the
issuance of (i) the Funded Shares in accordance with the terms of this Agreement
and (ii) the Warrant Shares upon exercise of the Warrants may result in dilution
of the outstanding shares of Common Stock, which dilution may be substantial
under certain market conditions. The Company further acknowledges that its
obligation (x) to issue Funded Shares at the applicable Closing and (y) to issue
Warrant Shares upon exercise of the Warrant is unconditional and absolute
regardless of the effect of any such dilution.
3.11 Intellectual Property. The Company and its subsidiaries own,
possess or can acquire on reasonable terms adequate trademarks, trade names and
other rights to inventions, know-how, patents, copyrights, confidential
information and other intellectual property rights necessary to conduct the
business now operated by them, or presently employed by them, and have not
received any notice of infringement of or conflict with asserted rights of
others with respect to any such rights that, if determined adversely to the
Company or any of its subsidiaries, would individually or in the aggregate have
a material adverse effect on the consolidated business or financial condition of
the Company and its subsidiaries taken as a whole.
3.12 Registration Rights; Rights of Participation. Except as described
on Schedule 3.12 hereto, (A) the Company has not granted or agreed to grant to
any person or entity any rights (including "piggy-back" registration rights) to
have any securities of the Company registered with the Commission or any other
governmental authority which has not been satisfied and (B) no person or entity,
including, but not limited to, current or former shareholders of the Company,
underwriters, brokers, agents or other third parties, has any right of first
refusal, preemptive right, right of participation, or any similar right to
participate in the transactions contemplated by this Agreement or any other
Transaction Document which has not been waived.
3.13 Trading on Nasdaq. The Common Stock is authorized for quotation on
the Nasdaq
11
National Market, and trading in the Common Stock on Nasdaq has not been
suspended. The Company is not in violation of any designation criteria of the
Nasdaq National Market and does not reasonably anticipate that the Common Stock
will lose its designation as a National Market Security.
3.14 Solicitation. Neither the Company nor any of its subsidiaries or
affiliates, nor any person acting on its or their behalf, (i) has engaged in any
form of general solicitation or general advertising (within the meaning of
Regulation D) in connection with the offer or sale of the Funded Shares or the
Warrants or (ii) has, directly or indirectly, made any offers or sales of any
security or solicited any offers to buy any security, under any circumstances
that would require registration of the Funded Shares or the Warrants under the
Securities Act.
3.15 Fees. The Company is not obligated to pay any compensation or
other fee, cost or related expenditure to any underwriter, broker, agent or
other representative in connection with the transactions contemplated hereby.
3.16 Foreign Corrupt Practices. To the knowledge of the Company,
neither the Company, nor any of its subsidiaries nor any director, officer,
agent, employee or other person acting on behalf of the Company or any
subsidiary, has (i) used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expenses relating to political activity,
(ii) made any direct or indirect unlawful payment to any foreign or domestic
government official or employee, (iii) violated any provision of the Foreign
Corrupt Practices Act of 1977, as amended, or made any bribe, rebate, payoff,
influence payment, kickback or other unlawful payment to any foreign or domestic
government official or employee.
3.17 Other Issuances of Securities. The Company has not issued (and
will not issue) any shares of Common Stock or shares of any series of preferred
stock or other securities or instruments convertible into, exchangeable for or
otherwise entitling the holder thereof to acquire shares of Common Stock which
would be subject to NASD Rule 4460 (or any successor rule) and which would be
integrated with the sale of the Funded Shares to Purchaser for purposes of
determining whether shareholder approval is required under such Rule.
3.18 Environmental Matters. Except as set forth in the Disclosure
Documents or on Schedule 3.18 hereof or as would not have a Material Adverse
Effect:
3.18.1 During the period that the Company or any of its
subsidiaries has leased or owned its properties or owned or operated any
facilities, there have been no material disposals, releases or threatened
releases of Hazardous Materials (as defined below) on, from or under such
properties or facilities in violation of applicable law. The Company has no
knowledge of any material disposals, releases or threatened releases of
Hazardous Materials on, from or under any of such properties or facilities,
which may have occurred prior to the Company or any such subsidiary having taken
possession of any of such properties or facilities in violation of applicable
law. For purposes of this Agreement, the terms "disposal," "release" and
"threatened release" shall have the definitions assigned thereto by the
Comprehensive Environmental
12
Response, Compensation and Liability Act of 1980, 42 U.S.C. Section 9601 et
seq., as amended ("CERCLA"). For the purposes of this Section "Hazardous
Materials" shall mean any hazardous or toxic substance, material or waste which
is or becomes prior to the Closing regulated under, or defined as a "hazardous
substance," "pollutant," "contaminant," "toxic chemical," "hazardous material,"
"toxic substance," or "hazardous chemical" under (1) CERCLA; (2) the Emergency
Planning and Community Right-to-Know Act, 42 U.S.C. Section 11001 et seq.; (3)
the Hazardous Materials Transportation Act, 49 U.S.C. Section 1801, et seq.; (4)
the Toxic Substances Control Act, 15 U.S.C. Section 2601 et seq.; (5) the
Occupational Safety and Health Act of 1970, 29 U.S.C. Section 651 et seq.; (6)
regulations promulgated under any of the above statutes; or (7) any applicable
state or local statute, ordinance, rule or regulation that has a scope or
purpose similar to those statutes identified above.
3.18.2 The Company or any of its subsidiaries has not received
any notice of, nor, to the Company's knowledge, are any of the Company's or any
such subsidiary's properties or facilities in violation of any federal, state or
local law, ordinance, regulation or order relating to industrial hygiene or to
the environmental conditions on, under or about such ground water condition.
During the time that the Company or any of its subsidiaries has owned or leased
its properties and facilities, neither the Company or any such subsidiaries nor,
to the Company's knowledge, any third party, has used, generated, manufactured
or stored on, under or about such properties or facilities or transported to or
from such properties or facilities any Hazardous Materials in violation of
applicable law.
3.18.3 During the time that the Company or any of its
subsidiaries has owned or leased its properties and facilities, there has been
no litigation brought or, to the Company's knowledge, threatened against the
Company or any such subsidiary, or any settlement reached by the Company or any
such subsidiary with, any party or parties alleging the presence, disposal,
release or threatened release of any Hazardous Materials on, from or under any
of such properties or facilities, in violation of applicable law.
3.18.4 During the period that the Company or any of its
subsidiaries has owned or leased its properties and facilities, no Hazardous
Materials have been transported from such properties or facilities to any site
or facility now listed or proposed for listing on the National Priorities List,
at 40 C.F.R. Part 300, or any list with a similar scope or purpose published by
any state authority.
3.19 Title. Except as set forth in Schedule 3.19, the Company and its
subsidiaries have good and marketable title in fee simple to all real property
and good and marketable title to all personal property owned by them which is
material to the business of the Company and its subsidiaries, in each case free
and clear of all liens, encumbrances and defects, except for liens, claims or
encumbrances as do not materially affect the value of such property and do not
interfere with the use made and proposed to be made of such property by the
Company and its subsidiaries. Any real property and facilities held under lease
by the Company and its subsidiaries are held by them under valid, subsisting and
enforceable leases with such exceptions as are not material and do not interfere
with the use made and currently proposed to be made of
13
such property and buildings by the Company and its subsidiaries.
3.20 Regulatory Permits. The Company and its subsidiaries possess all
material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their
respective businesses, and neither the Company nor any such subsidiary has
received any notice of proceedings relating to the revocation or modification of
any such certificate, authorization or permit.
3.21 No Material Non-Public Information. Except for the Company's
fourth quarter and year-end financial results, to the Company's knowledge, no
material fact (within the meaning of the federal securities laws of the United
States) exists with respect to the Company or any of its subsidiaries which has
not been disclosed publicly or to Purchaser. The Company warrants and represents
that to its knowledge there is no undisclosed material fact that is materially
adverse to the Company.
3.22 Eligibility for Form S-3. The Company is currently eligible to
register the resale of the the Funded Shares and the Warrant Shares for the
account of Purchaser on a registration statement on Form S-3 under the
Securities Act.
3.23 Regulatory Restrictions. To the Company's knowledge, there are no
applicable statutes, regulations or other laws regulating the businesses engaged
in by the Company (such as regulations of the Federal Communications Commission)
which would restrict the ownership by any person, including the Purchaser, of
the Common Stock.
4. COVENANTS OF THE COMPANY.
4.1 Corporate Existence. The Company shall, so long as Purchaser or any
affiliate of Purchaser beneficially owns any Securities (but in no event longer
than five (5) years from the First Closing Date), maintain its corporate
existence in good standing and shall pay all taxes owed by it when due except
for taxes which the Company reasonably disputes or as to which the failure to
pay could not reasonably be expected to have a material adverse effect on the
consolidated business or financial condition of the Company.
4.2 Provision of Information. The Company shall provide Purchaser with
copies of its annual reports on Form 10-K, quarterly reports on Form 10-Q,
current reports on Form 8-K and proxy statements and other materials sent to
shareholders, in each such case promptly after the filing thereof with the
Commission, until the exercise of all of the Warrants held by such Purchaser.
4.3 Form D; Blue-Sky Qualification. The Company agrees to file a Form D
with respect to the Securities as required under Regulation D and to provide a
copy thereof to Purchaser promptly after such filing. The Company shall, on or
before the applicable Closing, take such action as is necessary to qualify the
Funded Shares and the Warrants sold at such Closing for sale under applicable
state or "blue-sky" laws or obtain an exemption therefrom, and shall provide
14
evidence of any such action to Purchaser at or prior to such Closing.
4.4 Reporting Status. As long as Purchaser or any affiliate of
Purchaser beneficially owns any Securities and until the date on which any of
the foregoing may be sold to the public pursuant to Rule 144(k) (or any
successor rule or regulation), (i) the Company shall timely file with the
Commission all reports required to be so filed pursuant to the Exchange Act and
(ii) the Company shall not terminate its status as an issuer required by the
Exchange Act to file reports thereunder even if the Exchange Act or the rules or
regulations thereunder would permit such termination (other than a termination
resulting from the sale, conveyance or disposition of all or substantially all
of the assets of the Company, the effectuation of a transaction or series of
transactions, in which more than 50% of the voting power of the Company is
disposed of, or the consolidation, merger or other business combination of the
Company with or into any other entity, immediately following which the prior
shareholders of the Company fail to own, directly or indirectly, at least fifty
percent (50%) of the surviving entity). The Company agrees to file with the
Commission a Form 8-K describing the terms of the transactions contemplated by
this Agreement and the other Transaction Documents, as soon as possible, and in
any event on or before the tenth (10th) day following the First Closing Date, in
each case in the form required by the Exchange Act.
4.5 [intentionally omitted]
4.6 Reservation of Common Stock. The Company shall at all times have
authorized and reserved for issuance, free from any preemptive rights, solely
for the purpose of effecting the exercise of the Warrants, such number of its
shares of Common Stock as shall from time to time be sufficient to effect the
exercise of the Warrants in full (the "Reserved Amount"). The Company shall not
reduce the number of shares reserved for issuance hereunder without the written
consent of the Purchaser.
4.7 Use of Proceeds. The Company shall use the proceeds from the sale
of the Funded Shares and the Warrants for working capital and general corporate
purposes.
4.8 Quotation on Nasdaq. The Company shall (i) promptly following the
applicable Closing, secure the designation and quotation of the Funded Shares
and the Warrant Shares on the Nasdaq National Market and (ii) use its best
efforts to maintain the designation and quotation, or listing, of the Common
Stock on the Nasdaq National Market or the New York Stock Exchange or other
national securities exchange.
4.9 Use of Purchaser Name. The Company shall not use, directly or
indirectly, Purchaser's name in any advertisement, announcement, press release
or other similar communication unless it has received the prior written consent
of Purchaser (which consent shall not be unreasonably withheld) for the specific
use contemplated or as otherwise required by applicable law or regulation.
4.10 [intentionally omitted]
15
4.11 Company's Instructions to Transfer Agent. On or prior to each
Closing, the Company shall execute and deliver irrevocable instructions to its
transfer agent (the "Transfer Agent") (i) to issue certificates representing
Warrant Shares upon exercise of the Warrant in accordance with the its terms
upon receipt of a valid Exercise Notice (as defined in the Warrant) from
Purchaser, in the amount specified in such Exercise Notice in the name of
Purchaser or its nominee and (ii) to deliver such certificates to Purchaser no
later than the close of business on the later to occur of (A) the third (3rd)
business day following the related Exercise Date (as defined in the Warrant),
(B) the first business day following delivery of the original certificates, duly
endorsed, representing the Warrant being exercised if such delivery is effected
at or prior to 2:00 p.m., Arizona time, and (C) the second business day
following delivery of such original Warrant certificates if such delivery is
effected after 2:00 p.m., Arizona time. As long as purchases and sales of shares
of Common Stock are eligible for settlement at the Depository Trust Company
("DTC"), the Company shall instruct the transfer agent that, in lieu of
delivering physical certificates to Purchaser upon exercise of the Warrant, the
transfer agent may effect delivery of Warrant Shares by crediting the account of
Purchaser or its nominee at DTC for the number of shares for which delivery is
required hereunder within the time frame specified above for delivery of
certificates. The Company represents to and agrees with Purchaser that it will
not give any instruction to the Transfer Agent that will conflict with the
foregoing instruction or otherwise restrict Purchaser's right to exercise the
Warrant or to receive Warrant Shares in accordance with the terms of the
Warrant. In the event that the Company's relationship with the Transfer Agent
should be terminated for any reason, the Transfer Agent shall continue acting as
transfer agent pursuant to the terms hereof until such time that a successor
transfer agent is appointed by the Company and agrees to be bound by the terms
hereof.
4.12 [intentionally omitted]
4.13 [intentionally omitted]
4.14 Capital Raising Limitations. The Company will not, during the
period beginning on the date of the First Closing and ending on the date six (6)
months after the later of (i) the effective date of the First Registration
Statement (as defined in the Registration Rights Agreement) and (ii) the
effective date of the Second Registration Statement, issue any (a) security
which is convertible into, or exercisable or exchangeable for, a variable number
of shares of Common Stock which is based on the market price of the Common Stock
or (b) Common Stock (or any security convertible into, or exercisable or
exchangeable for, Common Stock) at an effective price per share of Common Stock
(after giving effect to the purchase price paid for the security and, if
applicable, the additional purchase price to be paid upon the exercise,
conversion or exchange of such security) which is less than ninety percent (90%)
of the closing price of the Common Stock on the Trading Day immediately
preceding the issuance of such Common Stock (the limitations referred to in this
sentence are collectively referred to as the "Capital Raising Limitations"). The
Capital Raising Limitations shall not apply to any transaction involving
issuances of securities as consideration in a merger, consolidation, acquisition
or sale of assets (in each case, the primary purpose of which is not to raise
equity capital) or pursuant to a strategic partnership or joint venture which is
formed for a bona fide commercial purpose, or as
16
consideration for the acquisition of a business, product or license by the
Company or in connection with the exercise of options by employees, directors or
consultants. The Capital Raising Limitations also shall not apply to (i) the
issuance of Common Stock in a transaction referred to in clause (b) above
pursuant to a public offering (other than an offering conducted pursuant to Rule
415 under the Securities Act), (ii) the issuance of securities upon exercise or
conversion of the Company's options, warrants or other convertible securities
outstanding as of the date hereof, or (iii) the grant of additional options or
warrants, or the issuance of additional securities, under any Company stock
option or restricted stock plan for the benefit of the Company's employees,
directors or consultants. Notwithstanding the foregoing, the Company may issue a
security described in clause (a) of this Section 4.14 only if it has satisfied
the following requirements:
(I) The Company shall have delivered notice to Purchaser (the "Transfer
Notice") which notice shall include (a) the terms and number of units of the
security and the consideration per unit which the Company desires to receive for
the securities (which, in the case where the Company shall have received an
offer to purchase such securities from a person other than Purchaser (a "Third
Party Offer"), shall be the consideration set forth in such offer) and (b) all
of the material terms and conditions, including the terms and conditions of
payment, upon which the Company proposes to transfer said securities (which, in
the case of a Third Party Offer, shall be the terms and conditions set forth in
the Third Party Offer).
(II) Upon the delivery of the Transfer Notice, the Purchaser shall have
an option to purchase any or all of the securities described therein. Such
option shall be exercisable by Purchaser by service of written notice upon the
Company within ten (10) days of receipt of the Transfer Notice.
(III) If the options created in clause (II) hereof are not exercised by
Purchaser within ten (10) days of service of the Transfer Notice, or if such
options are exercised only in part, then, within a period of sixty (60) days
beginning on the day following the date of expiration of the option period, the
Company may issue some or all of the securities sought to be issued as to which
such options were not exercised, at a price which is not less than ninety-five
percent (95%) of the price specified in the Transfer Notice and on terms and
conditions not less favorable to the Company than those specified in the
Transfer Notice.
5. [INTENTIONALLY OMITTED]
6. CONDITIONS TO CLOSING.
6.1 Conditions to Purchaser's Obligations at Both Closings. Purchaser's
obligations at each Closing, including without limitation its obligation to
purchase the Funded Shares and the applicable Warrant, are conditioned upon the
fulfillment of each of the following events:
6.1.1 the representations and warranties of the Company set
forth in this Agreement shall be true and correct in all material respects as of
the applicable Closing Date as if
17
made on such date;
6.1.2 the Company shall have complied with or performed all of
the agreements, obligations and conditions set forth in this Agreement that are
required to be complied with or performed by the Company on or before the
applicable Closing;
6.1.3 [intentionally omitted]
6.1.4 the Company shall have delivered to Purchaser a
certificate, signed by an officer of the Company, certifying that the conditions
specified in paragraphs 6.1.1 and 6.1.2 above have been fulfilled as of the
applicable Closing;
6.1.5 [intentionally omitted]
6.1.6 [intentionally omitted]
6.1.7 the Company shall have delivered to Purchaser an opinion
of counsel for the Company, dated as of the applicable Closing Date, in form and
substance reasonably acceptable to the parties;
6.1.8 the Company shall have executed and delivered the
Registration Rights Agreement;
6.1.9 the Common Stock shall be designated for quotation and
actively traded on the Nasdaq National Market;
6.1.10 as of the applicable Closing, there shall have been no
material adverse changes in the Company's consolidated business or financial
condition since the date of the Company's most recent audited financial
statements contained in the Disclosure Documents;
6.1.11 the Company shall have authorized and reserved for
issuance the aggregate number of shares of Common Stock issuable upon exercise
of the Warrants in full;
6.1.12 in the case of the Second Closing (if any), the First
Closing shall have been consummated; and
6.1.13 no additional consents, authorizations or approvals are
necessary for the execution or delivery by the Company of any of the Transaction
Documents or for the performance by the Company of any of its obligations under
the Transaction Documents.
6.2 Conditions to Company's Obligations at Closing. The Company's
obligations at each Closing are conditioned upon the fulfillment of each of the
following events:
6.2.1 the representations and warranties of Purchaser shall be
true and correct in all material respects as of the applicable Closing Date as
if made on such date; and
18
6.2.2 Purchaser shall have complied with or performed all of
the agreements, obligations and conditions set forth in this Agreement that are
required to be complied with or performed by Purchaser on or before the
applicable Closing.
6.3 Conditions to the Purchaser's Obligations at Second Closing.
Purchaser's obligations at the Second Closing, including without limitation its
obligation to purchase the Funded Shares and the Second Warrant, are conditioned
upon the fulfillment of the following events:
6.3.1 the Closing Sale Price for the Common Stock on the date
on which the Second Closing Notice is delivered pursuant to Section 1.1(a)
hereof is greater than the Closing Sale Price for the Common Stock on the
immediately preceding Trading Day;
6.3.2 the Company and the Purchaser have executed this
Agreement, the Registration Rights Agreement and the Warrant;
6.3.3 (a) the registration statement contemplated by Section
2(a) of the Registration Rights Agreement (the "First Registration Statement")
is and continues to be effective, or (b) the Closing Sale Price for the Common
Stock on the date on which the Second Closing Notice is delivered pursuant to
Section 1.1(a) hereof is $12.00 or greater;
6.3.4 subject to Section 1.5, the date of the Second Closing
is no later than March 31, 1999; and
6.3.5 all of the conditions described in Section 6.1 hereof
are met with respect to the Second Closing;
7. INDEMNIFICATION.
The Company agrees to indemnify and hold harmless Purchaser and its
officers, directors, employees and agents, and each person who controls
Purchaser within the meaning of the Securities Act or the Exchange Act (each, a
"Purchaser Indemnified Party") against any losses, claims, damages, liabilities
or reasonable out-of-pocket expenses (including the reasonable fees and
disbursements of counsel) as incurred, joint or several, to which it, they or
any of them, may become subject and not otherwise reimbursed, arising out of or
in connection with the breach by the Company of any of its representations,
warranties or covenants made herein.
Purchaser agrees, severally and not jointly, to indemnify and hold
harmless the Company and its officers, directors, employees and agents, and each
person who controls the Company within the meaning of the Securities Act or the
Exchange Act (each, a "Company Indemnified Party") (a Purchaser Indemnified
Party and a Company Indemnified Party are each hereinafter referred to as an
"Indemnified Party") against any losses, claims, damages, liabilities or
expenses (including the fees and disbursements of counsel) as incurred, joint or
several, to which it, they or any of them, may become subject and not otherwise
reimbursed, arising out of or in connection with the breach by Purchaser of any
of its representations, warranties or covenants made herein.
19
Promptly after receipt by an Indemnified Party of notice of the
commencement of any action by a third party pursuant to which indemnification
may be sought hereunder, such Indemnified Party will, if a claim in respect
thereof is to be made against the other party (the "Indemnifying Party"),
deliver to the Indemnifying Party a written notice of the commencement thereof
and the Indemnifying Party shall have the right to participate in and to assume
the defense thereof with counsel reasonably selected by the Indemnifying Party,
provided, however, that an Indemnified Party shall have the right to retain its
own counsel, with the reasonably incurred fees and expenses of such counsel to
be paid by the Indemnifying Party, if representation of such Indemnified Party
by the counsel retained by the Indemnifying Party would be inappropriate due to
actual or potential conflicts of interest under applicable standards of
professional conduct between such Indemnified Party and any other party
represented by such counsel in such proceeding. The failure to deliver written
notice to the Indemnifying Party within a reasonable time of the commencement of
any such action will not relieve the Indemnifying Party of any of its
obligations hereunder with respect to such action except to the extent such
failure is prejudicial to the Indemnifying Party's ability to defend any such
action.
No Indemnifying Party shall, without the prior written consent of the
Indemnified Party, effect any settlement of pending or threatened action in
respect of which an Indemnified Party is or is likely to be named as a party and
indemnity could have been sought hereunder by such Indemnified Party unless such
settlement includes an unconditional release of such Indemnified Party from all
liability on any claims that are the subject matter of such action. An
Indemnifying Party will not be liable for any settlement of any action or claim
effected without its written consent.
Nothing contained herein shall be deemed to entitle any party to
punitive damages.
8. MISCELLANEOUS.
8.1 Survival; Severability. The representations, warranties, covenants
and indemnities made by the parties herein shall survive the First Closing and
the Second Closing (if any) notwithstanding any due diligence investigation made
by or on behalf of the party seeking to rely thereon. In the event that any
provision of this Agreement becomes or is declared by a court of competent
jurisdiction to be illegal, unenforceable or void, this Agreement shall continue
in full force and effect without said provision; provided that in such case the
parties shall negotiate in good faith to replace such provision with a new
provision which is not illegal, unenforceable or void, as long as such new
provision does not materially change the economic benefits of this Agreement to
the parties.
8.2 Successors and Assigns. The terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective successors and
permitted assigns of the parties. Nothing in this Agreement, express or implied,
is intended to confer upon any party other than the parties hereto or their
respective successors and permitted assigns any rights, remedies, obligations or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement. The Purchaser may assign its rights hereunder, in connection
with any private
20
sale or transfer of the Warrant in accordance with the terms hereof, as long as,
as a condition precedent to such transfer, the transferee executes an
acknowledgment agreeing to be bound by the applicable provisions of this
Agreement, in which case the term "Purchaser" shall be deemed to refer to such
transferee as though such transferee were an original signatory hereto.
8.3 [intentionally omitted]
8.4 No Reliance; Representations by Purchaser. Each party acknowledges
that (i) it has such knowledge in business and financial matters as to be fully
capable of evaluating this Agreement, the other Transaction Documents and the
transactions contemplated hereby and thereby, (ii) it is not relying on any
advice or representation of the other party in connection with entering into
this Agreement, the other Transaction Documents or such transactions (other than
the representations made in this Agreement or the other Transaction Documents),
(iii) it has not received from such party any assurance or guarantee as to the
merits (whether legal, regulatory, tax, financial or otherwise) of entering into
this Agreement or the other Transaction Documents or the performance of its
obligations hereunder and thereunder, and (iv) it has consulted with its own
legal, regulatory, tax, business, investment, financial and accounting advisors
to the extent that it has deemed necessary, and has entered into this Agreement
and the other Transaction Documents based on its own independent judgment and on
the advice of its advisors as it has deemed necessary, and not on any view
(whether written or oral) expressed by such party. Purchaser acknowledges that
it can bear the economic risk of the purchase of the Funded Shares and related
Warrant, including the total loss of Purchaser's investment.
8.5 Injunctive Relief. The Company acknowledges that a breach by it of
its obligations hereunder will cause irreparable harm to Purchaser and that the
remedy or remedies at law for any such breach will be inadequate and agrees, in
the event of any such breach, in addition to all other available remedies, to an
injunction restraining any breach and requiring immediate and specific
performance of such obligations without the necessity of showing economic loss.
8.6 Governing Law; Jurisdiction. This Agreement shall be governed by
and construed under the laws of the State of New York without regard to the
conflict of laws provisions thereof. Each party hereby irrevocably submits to
the non-exclusive jurisdiction of the state and federal courts sitting in the
City of New York, borough of Manhattan, for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to
the jurisdiction of any such court, that such suit, action or proceeding is
brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof to such party at the address in effect for
notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any
manner permitted by law.
21
8.7 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument.
8.8 Headings. The headings used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this
Agreement.
8.9 Notices. Any notice, demand or request required or permitted to be
given by any party to any other party pursuant to the terms of this Agreement
shall be in writing and shall be deemed given (i) when delivered personally or
by verifiable facsimile transmission (with an original to follow) on or before
5:00 p.m., eastern time, on a business day or, if such day is not a business
day, on the next succeeding business day, (ii) on the next business day after
timely delivery to an overnight courier and (iii) on the third business day
after deposit in the U.S. mail (certified or registered mail, return receipt
requested, postage prepaid), addressed to the parties as follows:
If to the Company:
WavePhore, Inc.
▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇ ▇. ▇▇▇▇▇ (with a copy to the General Counsel)
Fax: ▇▇▇-▇▇▇-▇▇▇▇
If to Purchaser:
Castle Creek Technology Partners LLC
c/o Castle Creek Partners LLC
▇▇▇ ▇. ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Fax: ▇▇▇-▇▇▇-▇▇▇▇
8.10 Expenses. Except as otherwise specified herein, the Company and
Purchaser shall pay all costs and expenses that it incurs in connection with the
negotiation, execution, delivery and performance of this Agreement; provided
that the Company shall reimburse Purchaser for its reasonable out-of-pocket
expenses, including legal expenses, not to exceed ten thousand dollars
($10,000), in the aggregate, at each Closing.
8.11 Entire Agreement; Amendments. This Agreement and the other
Transaction Documents constitute the entire agreement between the parties with
regard to the subject matter hereof and thereof, superseding all prior
agreements or understandings, whether written or oral, between or among the
parties. Except as expressly provided herein, neither this Agreement nor any
term hereof may be amended except pursuant to a written instrument executed by
the Company, the initial Purchaser (if it then beneficially owns Securities) and
Purchasers holding at least two-thirds in interest of the Securities which were
acquired in a private transaction
22
(including the Purchaser if it still owns Securities), and no provision hereof
may be waived other than by a written instrument signed by the party against
whom enforcement of any such waiver is sought. No such amendment shall be
effective to the extent that, by its terms, it applies to less than all of the
Purchasers.
23
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
the date first-above written.
WAVEPHORE, INC.
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
By: __________________________
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Title: Executive Vice President and CFO
CASTLE CREEK TECHNOLOGY PARTNERS LLC
By: CASTLE CREEK PARTNERS LLC
Its: Managing Member
/s/ ▇▇▇▇ ▇▇▇▇▇▇▇
By: __________________________
Name: ▇▇▇▇ ▇▇▇▇▇▇▇
Title: Authorized Individual